Modulation of glycolytic ATP production
AssigneesLife Resuscitation Technologies, Inc., Organ, Inc.
InventorGregory M. Fahy
Life of this patent
Estimating the term…
Abstract
Delivery of fuel and cofactors augments ATP production in cells, and mitigates damages in ischemic or metabolically impaired tissues. The processes may be particularly effective in acute or chronic ischemic conditions, for reversing anesthesia, for treating diabetes, for producing or preventing coma due to lack of fuel or ATP, for reversing processes of aging, as dietary supplements, as performance enhancers, for example, in sports, for tissue transplantation and other surgery, and for cold storage or cryopreservation of tissues such as organs.
Claims43
A process for augmenting ATP production in an oxygen metabolism impaired tissue, comprising:
- administering to the tissue an effective amount of at least one exogenous compound selected from the group consisting of 3-PG, G3P, PEP, NAD.sup.+, coenzyme A and acetyl coenzyme A.
A process for mitigating damage due to an oxygen and/or fuel deficit in a cryopreserved organ, comprising:
- administering to the organ an effective amount of at least one compound selected from the group consisting of FBP, 3-PG, G3P, PEP, NAD.sup.+, coenzyme A, acetyl coenzyme A, carnitine and acetyl-carnitine.
A process for treating a patient afflicted with a glucose metabolism defect, comprising:
- administering to the patient at least one compound selected from the group consisting of FBP, 3-PG, PEP, NAD.sup.+, coenzyme A and acetyl coenzyme A in an amount effective to treat symptoms of said glucose metabolism defect.
A method for improving athletic performance, comprising administering to an individual before an athletic competition at least one compound selected from the group consisting of FBP, 3-PG, G3P, PEP, NAD.sup.+, coenzyme A in an amount effective to augment ATP levels in said individual during said competition.
An ATP augmentation composition, comprising at least one compound selected from the group consisting of FBP, G3P, 3-PG, PEP, NAD.sup.+, coenzyme A and acetyl coenzyme A in a timed release form.
A process for augmenting ATP production in an organ, comprising administering to said organ exogenous an effective amount of pyruvate and FBP.
An ATP augmentation composition comprising:
- a pharmaceutically acceptable carrier;
- and
- at least one compound selected from the group consisting of 3-PG, PEP, and acetyl coenzyme A.
A process for treating or preventing energy deficit associated damage to a tissue in oxygen or fuel deficit by augmenting ATP production in said tissue, comprising:
- administering to said tissue an effective amount of at least one exogenous compound selected from the group consisting of 3-PG, G3P, PEP, NAD.sup.+, coenzyme A and acetyl coenzyme A.
An ATP augmentation composition comprising:
- a carrier acceptable for pharmaceutical injection;
- and
- at least one compound selected from the group consisting of G3P, NAD.sup.+ and coenzyme A.
Dependencies are inferred from the claim text.